Genomics

Together, We Beat Cancer

We perform DNA and RNA Next Generation-Sequencing (NGS) based genetic testing to generate high-quality molecular genetic data. This is achieved by analyzing Somatic and Germline variants, thereby empowering oncologists to make genomic data-driven personalized treatment decisions for their cancer patients. Clinically relevant genomic biomarkers are analyzed and prioritized based on the strength of the clinical evidence, which provides insights into relevant therapeutic options (targeted and Immunotherapy).

Our Liquid biopsy panel utilizes the ctDNA approach to provide comprehensive information on the biology of the tumor in terms of its current status and its response to therapy from peripheral blood.

Our interdisciplinary team of cancer researchers, bioinformaticians, and data scientists uses in-house developed custom algorithms that include complex mathematical and statistical models for in-depth curation and correlation of published scientific findings and clinical research to provide the most updated and best treatment recommendations.

Somatic Panels

Somatic mutation tests in cancer are typically performed on tumor tissue (FFPE block/Fresh tissue) to identify somatic mutations, which might help identify the clinically actionable genomic alterations for cancer patients. Our TARGT (Tumor-Associated Drug Response by Genomic Testing) portfolio of genomic tests is validated to identify somatic mutations in the tumor tissue with high sensitivity and specificity to detect even low-frequency genomic alterations/aberrations/mutations that drive cancer.

All the tests under the TARGT portfolio identify genomic variants associated with approved treatment and clinical trials. TARGT tests report actionable and targetable somatic mutations, which include SNVs, Indels, CNAs, Gene fusions/Splice variants, and Genomic Signatures like Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI). 

Click on the below icons to know more about our Somatic Gene-Mutated Cancer Panels


Hereditary Cancer Test

Genomic variations/mutations/aberrations in the genes you are born with can increase your cancer risk. Our NGS (Next-Generation Sequencing) based Hereditary Cancer genetic panels analyze genes associated with cancer risk DDR (DNA Damage Repair), Mismatch Repair (MMR), and HRR (Homologous Recombination Repair) pathways. The panel includes genes associated with familial and hereditary cancers (Breast, Ovarian, Prostate, Pancreatic, Colon, etc).

As per ACMG guidelines, the detected variants are classified as pathogenic, likely pathogenic, VUS (Variant of Unknown Significance), likely benign, and benign. This may contribute to a high, moderate, or low cancer risk.

Some of the Germline variants, like in the BRCA gene, help identify cancer risk and help in making PARP (Poly-ADP-Ribose Polymerase) inhibitor targeted therapy treatment decisions.

Click on the below icon to know more about our Hereditary Cancer Test


Liquid Biopsy Cancer Gene Panels

Liquid biopsy is a minimally invasive blood-based assay that has a role in monitoring, prognostication, and therapeutic treatment-related decisions for cancer patients. The assay isolates and detects tumor genomes and associated genomic alterations such as SNVs/InDels, CNAs, and Gene Fusions/Splice Variants from peripheral blood (ctDNA).

Liquid biopsies have been recognized as valuable diagnostic and monitoring tools. With FDA approving the use of liquid biopsies for Non-Small Cell Lung Cancer and other solid tumors, oncologists around the globe are utilizing this technique for various cancer patients.

The liquid biopsy technique involves drawing blood from the cancer patient and analyzing the tumor or tumor content in the bloodstream. Compared to tissue biopsies, liquid biopsies are quicker, easier, less painful, and minimally invasive as they require only the patient's blood for further analysis. The technique involves extracting tumor DNA from blood followed by NGS analysis for precise cancer management.

Click on the below icon to know more about our Liquid Biopsy Cancer Gene Panels


loader